Delivery Order SPE2DB22D2214-SPE2DB25FS5UE
- Not listed
- The Defense Logistics Agency awarded a $1,787.46 delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Teriparatide 560 mcg/2.24 mL pens. This firm fixed price contract, with an ultimate completion date of December 10, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was made through open competition without set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $4,076.99 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pens on May 27, 2025, with an ultimate completion date of May 28, 2025. This firm fixed price, competitively awarded contract involves no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,168.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Teriparatide 560mcg/2.24ml pens. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award is non-set-aside and was competitively awarded. Performance will be completed by July 25,...
- The Defense Logistics Agency awarded a $13,951.16 delivery order to AmerisourceBergen Drug Corp for teriparatide 560 mcg/2.24 mL pens on December 1, 2025, with completion scheduled for December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,758.48 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560 mcg/2.24 mL pens on November 4, 2025, with completion scheduled for November 5, 2025. This non-competitive delivery order represents a small-value pharmaceutical procurement supporting federal medical supply needs. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $5,286.27 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Teriparatide 560mcg/2.24ml pens on September 8, 2025, with completion scheduled for September 9, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Teriparatide 560mcg/2.24mL pens valued at $6,554.84 with a firm fixed price structure. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 30, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery from its corporate office location in the same city. This...
- The Defense Logistics Agency awarded a delivery order valued at $19,742.16 to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Teriparatide 560mcg/2.24mL pens. This firm fixed-price delivery order, with an ultimate completion date of November 7, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Teriparatide 560mcg/2.24mL pens valued at $2,158.86. This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion deadline of December 2, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement...
- The Defense Logistics Agency awarded a delivery order valued at $3,388.67 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pens on May 30, 2025, with completion scheduled for June 2, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitive award to the pharmaceutical distributor's Conshohocken, Pennsylvania corporate office. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS5UEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,361.19 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24mL pens on July 16, 2025, with an ultimate completion date of July 17, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This transaction represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The delivery order is issued under AmerisourceBergen's comprehensive pharmaceutical prime vendor agreement with DLA, which enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. Teriparatide is a recombinant parathyroid hormone analog used primarily in osteoporosis treatment, reflecting the Defense Health Agency's medical supply requirements. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen demonstrates consistent capability in fulfilling federal healthcare needs through competitive procurement processes, with its portfolio spanning specialty medications, brand-name and generic drugs, vaccines, and specialized medical supplies across multiple therapeutic domains for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 7/16/25 |